CL2018001677A1 - Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert - Google Patents
Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ertInfo
- Publication number
- CL2018001677A1 CL2018001677A1 CL2018001677A CL2018001677A CL2018001677A1 CL 2018001677 A1 CL2018001677 A1 CL 2018001677A1 CL 2018001677 A CL2018001677 A CL 2018001677A CL 2018001677 A CL2018001677 A CL 2018001677A CL 2018001677 A1 CL2018001677 A1 CL 2018001677A1
- Authority
- CL
- Chile
- Prior art keywords
- treated
- treatment
- ert
- patients
- fabry disease
- Prior art date
Links
- 208000024720 Fabry Disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- LXBIFEVIBLOUGU-DPYQTVNSSA-N migalastat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O LXBIFEVIBLOUGU-DPYQTVNSSA-N 0.000 abstract 1
- 229950007469 migalastat Drugs 0.000 abstract 1
- 230000002861 ventricular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
SE PROVEEN REGÍMENES DE DOSIFICACIÓN PARA EL TRATAMIENTO DE LA ENFERMEDAD DE FABRY EN UN PACIENTE. ALGUNOS MÉTODOS SE RELACIONAN CON EL TRATAMIENTO DE PACIENTES CON FABRY NO TRATADOS PREVIAMENTE O TRATADOS CON ERT. ALGUNOS MÉTODOS COMPRENDEN ADMINISTRAR AL PACIENTE APROXIMADAMENTE 123 MG DE EQUIVALENTES DE BASE LIBRE DE MIGALASTAT PARA MEJORAR LA MASA VENTRICULAR IZQUIERDA Y/O PARA MEJORAR LA GLOBOTRIAOSILCERAMIDA EN PODOCITOS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/213,920 US9999618B2 (en) | 2007-04-26 | 2016-07-19 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018001677A1 true CL2018001677A1 (es) | 2019-02-01 |
Family
ID=59416847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018001677A CL2018001677A1 (es) | 2016-07-19 | 2018-06-20 | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12070453B2 (es) |
| EP (5) | EP4356911A1 (es) |
| JP (4) | JP6752270B2 (es) |
| KR (3) | KR20230061563A (es) |
| CN (1) | CN109661230A (es) |
| AR (1) | AR109103A1 (es) |
| AU (3) | AU2017298376A1 (es) |
| CA (1) | CA3031249A1 (es) |
| CL (1) | CL2018001677A1 (es) |
| CO (1) | CO2018006358A2 (es) |
| IL (2) | IL313907A (es) |
| MX (2) | MX395523B (es) |
| NZ (2) | NZ750752A (es) |
| TW (2) | TWI875676B (es) |
| WO (1) | WO2018017721A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE027569T2 (en) | 2006-05-16 | 2016-10-28 | Amicus Therapeutics Inc | Preparation for the treatment of Fabry disease |
| CA2715407C (en) | 2008-02-12 | 2022-07-26 | Elfrida Benjamin | Method to predict response to pharmacological chaperone treatment of diseases |
| TWI875676B (zh) * | 2016-07-19 | 2025-03-11 | 美商阿米庫斯醫療股份有限公司 | 治療ert初治的和已經歷ert的患者中之法布瑞氏症 |
| US12020820B1 (en) * | 2017-03-03 | 2024-06-25 | Cerner Innovation, Inc. | Predicting sphingolipidoses (fabry's disease) and decision support |
| AU2018277756A1 (en) | 2017-05-30 | 2020-01-23 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| SI4062916T1 (sl) | 2017-05-30 | 2025-04-30 | Amicus Therapeutics, Inc. | Zdravljenje bolnikov s Fabryjem, ki imajo določene mutacije |
| EP3749307A1 (en) * | 2018-02-06 | 2020-12-16 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
| CA3090499A1 (en) * | 2018-02-06 | 2019-08-15 | Amicus Therapeutics, Inc. | Use of migalastat for the treatment of patients with classic fabry disease |
| MX2021002070A (es) * | 2018-08-20 | 2021-07-15 | Amicus Therapeutics Inc | Metodos para tratar la enfemedad de fabry en pacientes que tienen una mutacion en el gen gla. |
| TW202042812A (zh) * | 2019-01-22 | 2020-12-01 | 美商阿米庫斯醫療股份有限公司 | 減少法布瑞氏症患者中之腦血管事件之方法 |
| MX2021015352A (es) * | 2019-06-11 | 2022-04-06 | Amicus Therapeutics Inc | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal. |
| AU2020327019A1 (en) | 2019-08-07 | 2022-03-03 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| EP4103178A4 (en) * | 2020-02-10 | 2024-03-20 | Amicus Therapeutics, Inc. | Methods of treating fabry disease |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
| KR102471225B1 (ko) | 2021-11-18 | 2022-11-28 | 박기용 | 어플리케이션을 통한 소비자 및 농장 연결 시스템 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990011353A1 (en) | 1989-03-24 | 1990-10-04 | Research Corporation Technologies, Inc. | Recombinant alpha-galactosidase, a therapy for fabry disease |
| WO1992000277A1 (en) | 1990-06-29 | 1992-01-09 | Nippon Shinyaku Co., Ltd. | Piperidine derivative |
| US6270954B1 (en) | 1996-04-10 | 2001-08-07 | The Regents Of The University Of California | Correction of genetic defects using chemical chaperones |
| JP2000509971A (ja) | 1996-04-10 | 2000-08-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 化学的シャペローンを用いる遺伝的欠陥の修正 |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| MX344587B (es) | 2003-01-31 | 2016-12-20 | Mount Sinai School Of Medicine Of New York Univ | Metodo para incrementar la estabilidad in vitro e in vivo de enzimas asociadas al transtorno lisosomal. |
| US7446098B2 (en) | 2003-02-18 | 2008-11-04 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiencies |
| CA2545435C (en) | 2003-11-12 | 2014-08-19 | Amicus Therapeutics Inc. | Hydroxy piperidine derivatives to treat gaucher disease |
| ES2572148T3 (es) | 2005-05-17 | 2016-05-30 | Amicus Therapeutics Inc | Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados |
| CN104771402A (zh) | 2005-06-08 | 2015-07-15 | 阿米库斯治疗学公司 | 溶酶体酶编码基因突变相关的cns紊乱的治疗 |
| US7955262B2 (en) | 2005-07-26 | 2011-06-07 | Syneron Medical Ltd. | Method and apparatus for treatment of skin using RF and ultrasound energies |
| AU2006272497B2 (en) | 2005-07-27 | 2012-07-19 | University Of Florida Research Foundation, Inc. | Small compounds that correct protein misfolding and uses thereof |
| HUE027569T2 (en) * | 2006-05-16 | 2016-10-28 | Amicus Therapeutics Inc | Preparation for the treatment of Fabry disease |
| AU2015230773B2 (en) | 2006-05-16 | 2017-09-28 | Amicus Therapeutics Inc. | Assays for diagnosing and evaluating treatment options for fabry disease |
| WO2008034628A1 (en) | 2006-09-22 | 2008-03-27 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Aripiprazole hemifumarate and process for its preparation |
| AU2008232614A1 (en) | 2007-03-30 | 2008-10-09 | Amicus Therapeutics, Inc. | Method for the treatment of Fabry disease using pharmacological chaperones |
| CA2715407C (en) | 2008-02-12 | 2022-07-26 | Elfrida Benjamin | Method to predict response to pharmacological chaperone treatment of diseases |
| CA2829947C (en) * | 2011-03-11 | 2019-01-15 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of fabry disease |
| JP2013255488A (ja) * | 2012-05-18 | 2013-12-26 | Saitama Medical Univ | 拡張期心不全非ヒトモデル動物及びその製造方法、並びに、拡張期心不全予防乃至症状改善活性を有する物質のスクリーニング方法 |
| TWI875676B (zh) * | 2016-07-19 | 2025-03-11 | 美商阿米庫斯醫療股份有限公司 | 治療ert初治的和已經歷ert的患者中之法布瑞氏症 |
-
2017
- 2017-07-19 TW TW106124148A patent/TWI875676B/zh active
- 2017-07-19 EP EP23219947.1A patent/EP4356911A1/en active Pending
- 2017-07-19 US US16/318,905 patent/US12070453B2/en active Active
- 2017-07-19 CN CN201780054621.XA patent/CN109661230A/zh active Pending
- 2017-07-19 EP EP23219937.2A patent/EP4324521A3/en active Pending
- 2017-07-19 AU AU2017298376A patent/AU2017298376A1/en not_active Abandoned
- 2017-07-19 KR KR1020237013747A patent/KR20230061563A/ko not_active Ceased
- 2017-07-19 MX MX2018007669A patent/MX395523B/es unknown
- 2017-07-19 WO PCT/US2017/042872 patent/WO2018017721A1/en not_active Ceased
- 2017-07-19 NZ NZ750752A patent/NZ750752A/en unknown
- 2017-07-19 JP JP2018510380A patent/JP6752270B2/ja active Active
- 2017-07-19 EP EP24168024.8A patent/EP4378524A3/en active Pending
- 2017-07-19 NZ NZ790449A patent/NZ790449A/en unknown
- 2017-07-19 TW TW112140206A patent/TW202408513A/zh unknown
- 2017-07-19 IL IL313907A patent/IL313907A/en unknown
- 2017-07-19 EP EP17745612.6A patent/EP3487502A1/en not_active Withdrawn
- 2017-07-19 CA CA3031249A patent/CA3031249A1/en active Pending
- 2017-07-19 EP EP24168026.3A patent/EP4389213A3/en active Pending
- 2017-07-19 KR KR1020197004780A patent/KR20190030729A/ko not_active Ceased
- 2017-07-19 KR KR1020247003290A patent/KR20240017126A/ko active Pending
- 2017-07-19 AR ARP170102027A patent/AR109103A1/es not_active Application Discontinuation
-
2018
- 2018-06-20 CO CONC2018/0006358A patent/CO2018006358A2/es unknown
- 2018-06-20 MX MX2022011334A patent/MX2022011334A/es unknown
- 2018-06-20 CL CL2018001677A patent/CL2018001677A1/es unknown
-
2019
- 2019-01-17 IL IL264301A patent/IL264301A/en unknown
- 2019-05-22 JP JP2019096045A patent/JP2019178140A/ja not_active Withdrawn
-
2021
- 2021-11-08 JP JP2021181583A patent/JP2022033749A/ja not_active Withdrawn
-
2023
- 2023-05-18 US US18/199,120 patent/US20230321065A1/en active Pending
- 2023-07-20 AU AU2023206175A patent/AU2023206175B2/en active Active
- 2023-11-13 JP JP2023192778A patent/JP2024026079A/ja active Pending
-
2025
- 2025-08-16 AU AU2025217396A patent/AU2025217396A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001677A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| MX2024010140A (es) | Nuevos metodos. | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| CY1124135T1 (el) | Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε | |
| MX2023005628A (es) | Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry. | |
| MX2021002322A (es) | Nuevos metodos. | |
| MX2022004137A (es) | Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| NI201700024A (es) | Tratamientos médicos a base de anamorelina | |
| CY1123501T1 (el) | Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| WO2019157056A8 (en) | Treatment of patients with classic fabry disease | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| AR117861A1 (es) | Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
| MX385725B (es) | Composición farmacéutica que comprende sumatriptán para tratamiento de migraña. | |
| EA201692163A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом | |
| EA202090452A1 (ru) | Соединения для лечения болезни фон гиппеля-линдау | |
| UA116484U (uk) | Cпосіб лікування артеріальної гіпертензії з метаболічним синдромом | |
| GT201700041A (es) | Tratamientos médicos a base de anamorelina | |
| UA115063U (xx) | Спосіб лікування собак із больовим синдромом при панкреатиті | |
| UA96488U (uk) | Спосіб лікування порушень гемоваскулярного гемостазу у хворих на ішемічну хворобу серця | |
| UA95687U (uk) | Лікарський засіб для терапії захворювань передміхурової залози в формі супозиторія |